Cystic Fibrosis (CF) Market Outlook

Thelansis’s “Cystic Fibrosis (CF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cystic Fibrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cystic Fibrosis (CF) Overview

Cystic fibrosis (CF) is a life-limiting autosomal recessive multisystem disorder caused by mutations in the CFTR gene — encoding the cystic fibrosis transmembrane conductance regulator chloride channel — resulting in defective epithelial ion transport, viscous secretion accumulation, and progressive organ damage predominantly affecting the lungs, pancreas, liver, and reproductive tract. Over 2,000 CFTR mutations are recognised, classified by functional consequence — with F508del, present in approximately 85% of patients, representing the most prevalent variant. Chronic airway infection — predominantly Pseudomonas aeruginosa and Staphylococcus aureus — neutrophilic inflammation, bronchiectasis, and progressive respiratory failure define the pulmonary disease course. Diagnosis integrates newborn screening, sweat chloride testing, and CFTR genotyping. CFTR modulator therapy has transformed the therapeutic landscape; elexacaftor-tezacaftor-ivacaftor — a triple combination corrector-potentiator regimen — delivers unprecedented improvements in lung function, nutritional status, and quality of life in eligible patients carrying at least one F508del allele, fundamentally altering disease trajectory. Airway clearance physiotherapy, inhaled mucolytics, bronchodilators, and antimicrobial management of pulmonary exacerbations remain essential alongside modulator therapy. Pancreatic enzyme replacement, fat-soluble vitamin supplementation, and CF-related diabetes management address extrapulmonary manifestations. Lung transplantation remains an option for end-stage respiratory disease. Prognosis has improved dramatically with modulator therapy; multidisciplinary care, psychosocial support, and fertility counselling are integral to holistic, patient-centred long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)